Order byBest matchMost fresh

Hims & Hers Health, food and drug administration

Digest more
Top News
Impacts
The Wall Street Journal |
The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.
Business Insider |
Moreover, Bank of America also published bearish guidance, given that the company is expected to stop compounded semaglutide drug sales by May 22nd.

Read more on News Digest

Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on se
Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.
‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)
Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance,
Why April Could Be a Huge Month for Eli Lilly Stock
A key drug that investors are going to be following this year is orforglipron, a once-daily pill that Eli Lilly is developing for weight loss and other indications. The early data has been encouraging,
Modern Healthcare2d
Eli Lilly denies affiliation with Hims & Hers
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.
Eli Lilly says company has no affiliation with Hims & Hers
In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be
Feedback